A Potential Pathogenic Link Between Cancer of Female Reproductive System and Infertile Women Treated With Assisted Reproduction Techniques.
Assisted reproduction technology
endometrial
fertility drugs
gynecological cancer
ovarian
review
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
01
02
2021
revised:
02
03
2021
accepted:
05
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
Prevention and treatment of infertility remains a priority for developed countries where a large proportion of women undergo in vitro fertilization (IVF) after ovarian stimulation. Latest data suggest that, in the USA alone, almost eight million women of fertile age will have sought medical advice for fertility problems by 2025. However, over the last years, attention has been increasingly focused, and questions have risen, on the long-term health effects in women who underwent assisted reproductive technologies (ARTs). Since the emergence of ART, reports highlight a possible connection of ovarian stimulation and several types of gynaecological cancer, including ovarian, endometrial and cervical types, but due to limited scientific evidence, such a speculation is still under investigation. The objective of this review is to summarize the latest data of ovarian hyperstimulation and IVF, associated with the risk of gynecological tract cancer development.
Identifiants
pubmed: 33910816
pii: 35/3/1393
doi: 10.21873/invivo.12391
pmc: PMC8193339
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1393-1399Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
N Engl J Med. 1994 Sep 22;331(12):771-6
pubmed: 8065405
Front Endocrinol (Lausanne). 2019 May 24;10:313
pubmed: 31191449
Hum Reprod. 1998 Jul;13(7):1968-74
pubmed: 9740459
Lancet. 1999 Nov 6;354(9190):1586-90
pubmed: 10560672
Br J Cancer. 2009 Jun 2;100(11):1824-31
pubmed: 19436296
Hum Reprod. 2015 Jan;30(1):222-31
pubmed: 25376453
Eur J Obstet Gynecol Reprod Biol. 2015 Dec;195:52-60
pubmed: 26476799
Fertil Steril. 2013 Dec;100(6):1660-6
pubmed: 24011610
Fertil Steril. 2015 May;103(5):1305-12
pubmed: 25792249
Lancet Oncol. 2008 Nov;9(11):1108-11
pubmed: 19012860
Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10
pubmed: 10883018
Fertil Steril. 2016 Dec;106(7):1617-1626
pubmed: 27573989
Am J Epidemiol. 1992 Nov 15;136(10):1184-203
pubmed: 1476141
Fertil Steril. 2002 Feb;77(2):324-7
pubmed: 11821091
Cochrane Database Syst Rev. 2017 Mar 25;3:CD010931
pubmed: 28349511
Hum Reprod Update. 2013 Mar-Apr;19(2):105-23
pubmed: 23255514
Curr Opin Obstet Gynecol. 2017 Aug;29(4):195-201
pubmed: 28538003
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):953-962
pubmed: 28108444
J Cancer Res Clin Oncol. 2016 Jan;142(1):287-93
pubmed: 26337160
Hum Reprod. 2015 Aug;30(8):1952-63
pubmed: 26113657
Fertil Steril. 1996 Jan;65(1):13-8
pubmed: 8557128
Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):8042-8059
pubmed: 30536354
Hum Reprod. 2011 Dec;26(12):3456-65
pubmed: 22031719
Fertil Steril. 2013 Jun;99(7):2031-6
pubmed: 23552324
Fertil Steril. 2016 Mar;105(3):781-785
pubmed: 26698676
Fertil Steril. 2014 Dec;102(6):1723-8
pubmed: 25256924
Fertil Steril. 2015 Nov;104(5):1218-26
pubmed: 26271227
Cancer J. 2015 Mar-Apr;21(2):104-10
pubmed: 25815850
Fertil Steril. 2013 Apr;99(5):1189-96
pubmed: 23375197
Fertil Steril. 1998 Dec;70(6):1049-55
pubmed: 9848294
Gynecol Endocrinol. 2012 Oct;28(10):809-14
pubmed: 22475084
Am J Obstet Gynecol. 2005 Sep;193(3 Pt 1):668-74
pubmed: 16150258
Hum Reprod. 2013 Oct;28(10):2813-21
pubmed: 23943795